Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Indecainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indecainide SCHEMBL121202 | 0.97 | KDM4E (0.42) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL29397898 | 0.96 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL11086669 | 0.96 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1MTTP | |
| Indecainide SCHEMBL121201 | 0.96 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL11078673 | 0.94 | KDM4E (0.43) | KDM4EALDH1A1TDP1APEX1MTTP | |
| SCHEMBL11090876 | 0.83 | KDM4E (0.41) | KDM4EALDH1A1TDP1MTTP | |
| SCHEMBL10995584 | 0.82 | APEX1 (0.40) | TDP1APEX1MTTP | |
| Hydrochloric Acid SCHEMBL11090502 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1TDP1MTTP | |
| SCHEMBL11092008 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1MTTP | |
| SCHEMBL11091509 | 0.80 | ALDH1A1 (0.42) | KDM4EALDH1A1TDP1MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5962477-A | USING LOPERAMIDE | ADOLOR CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |